What Happened
- India's recently concluded Free Trade Agreements — most significantly with the European Union — are expected to substantially expand export opportunities for the pharmaceutical, medical devices, and healthcare services sectors.
- The India-EU FTA, concluded in January 2026 and hailed as the "Mother of All Deals," opens a US$572 billion EU healthcare and pharmaceutical market to Indian firms, with tariff eliminations on pharmaceuticals (currently up to 11%) and medical devices (currently up to 27.5%).
- India's pharmaceutical exports to the EU were approximately US$6 billion in FY25; analysts project significant growth as tariff and non-tariff barriers ease under the agreement.
- Commerce Minister Piyush Goyal specifically highlighted FTAs as opening new market access for pharma, healthcare, and medical technology (medtech) companies, positioning India's global role as "Pharmacy of the World" on a more formal treaty footing.
- The agreement also includes provisions for AYUSH (traditional medicine) services — allowing AYUSH practitioners qualified in India to operate in EU member states where no conflicting regulations exist, and enabling establishment of AYUSH wellness centres in Europe.
Static Topic Bridges
India's Pharmaceutical Sector — Global Standing
India is the world's largest supplier of generic medicines by volume, supplying approximately 20% of global generic drug exports. The sector is colloquially referred to as the "Pharmacy of the World," with exports reaching US$27.8 billion in FY24. India supplies 50% of Africa's generic drug demand, 40% of the US's generic drug demand, and a significant share of the UK's National Health Service drug requirements. Key strengths include cost-competitiveness (30-40% cheaper than Western producers), a large pool of chemistry and biotech talent, and a robust WHO-GMP certified manufacturing base concentrated in Hyderabad, Ahmedabad, and Mumbai.
- India has the highest number of US FDA-approved pharmaceutical manufacturing plants outside the US (~600+ facilities).
- Key export products: formulations, Active Pharmaceutical Ingredients (APIs), biosimilars, vaccines.
- India's vaccine exports include 60% of WHO-procured vaccines globally (pre-COVID baseline).
- FY25 pharma exports: approximately US$27-28 billion (formulations dominate at ~70% share).
Connection to this news: The India-EU FTA's tariff eliminations are particularly consequential for pharma MSMEs that have the product capability to access European markets but have been priced out by the combination of high duties and costly regulatory compliance procedures.
Free Trade Agreements — Structure and India's FTA Strategy
A Free Trade Agreement (FTA) is a treaty between two or more countries that reduces or eliminates tariffs, quotas, and other trade barriers on goods and services traded between them. India's FTA strategy has evolved significantly since 2022 — after a decade of limited progress, India concluded agreements with the UAE (2022), Australia (2022), and the EU (2026), with nine comprehensive FTAs now covering 38 countries. These FTAs collectively grant Indian exporters preferential access to nearly two-thirds of global trade.
- India-EU FTA: immediate duty-free access for 70.4% of Indian tariff lines, covering 90.7% of India's export value.
- India-UK FTA: covers life sciences as a priority sector; expected to boost pharma and medtech access.
- FTA expansion: India's network is projected to cover ~71% of total export basket by 2026, up from ~22% in 2019.
- Rules of Origin provisions in FTAs determine which products qualify for preferential tariffs — a key technical detail for pharma exporters.
Connection to this news: For pharma, FTAs are not simply tariff-reduction tools — they also typically include Mutual Recognition Agreements (MRAs) on pharmaceutical standards and regulatory cooperation clauses that reduce duplicative testing costs, which are often larger barriers than tariffs for regulated products.
Medical Technology (MedTech) and AYUSH Exports
Beyond traditional pharmaceuticals, India is expanding its footprint in medical devices and AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy) products and services. India's medical devices market is valued at approximately US$16 billion (FY25), but imports dominate — India imports ~75-80% of high-end medical devices. FTAs with developed countries could support both India's export of lower-cost devices (surgical instruments, disposables, medical textiles) and potentially stimulate technology transfer for higher-end devices.
- India's medical device exports: approximately US$3.5-4 billion annually.
- AYUSH exports (herbal products, supplements, traditional formulations): US$500+ million annually; government target of US$10 billion by 2030.
- Ministry of AYUSH established in 2014; the AYUSH Premium Mark and Ayurvedic Proprietary Medicine category help standardise export-quality products.
- The India-EU FTA's AYUSH provisions enable establishing wellness clinics and exchanges to facilitate traditional medicine trade.
Connection to this news: The FTA's AYUSH provisions represent a novel form of services-trade integration — allowing India to export not just physical pharmaceutical products but also healthcare expertise and traditional medicine practices, diversifying the sector's export basket.
Key Facts & Data
- India-EU FTA: concluded January 2026 (hailed as "Mother of All Deals")
- EU pharma market accessible: US$572 billion
- EU tariff on Indian pharmaceuticals: up to 11% (to be eliminated)
- EU tariff on Indian medical devices: up to 27.5% (to be eliminated)
- India pharma exports to EU (FY25): ~US$6 billion
- India total pharma exports (FY24): ~US$27.8 billion
- India's global generic drug supply share: ~20% by volume
- US FDA-approved plants in India: 600+ (highest outside US)
- India FTA coverage: ~two-thirds of global trade (9 FTAs, 38 countries)
- FTA basket coverage: projected ~71% of India's total exports by 2026 (vs 22% in 2019)